

<b>File reference</b>	W18FOI634
<b>Key words</b>	Information regarding Anaesthetic Agents
<b>Date of release</b>	22/03/2019
<b>Attachments</b>	Yes

## Freedom of Information Act Disclosure log - Reply Extract

You asked

**I would like to know the total volume and total amount spent individually for EACH of the following agents sevoflurane, desflurane, isoflurane, nitrous oxide, and propofol PER YEAR between 2006 and 2018 as shown below:**

**- Total (annual) volume purchased for EACH agent (incl. sevoflurane, desflurane, isoflurane, nitrous oxide, and propofol) PER YEAR for 2006-2018 (in millilitres or litres).**

**- Total (annual) volume used for EACH agent PER YEAR for 2006-2018 (in millilitres or litres).**

**- Total (annual) amount spent on EACH agent PER YEAR for 2006-2108 (in pounds sterling).**

**If it is easier to provide another unit of measure, please provide details so that I can calculate the volume. Also, please state whether the total amount spent includes or excludes VAT.**

**If not violating commercial sensitivity, please also include who the manufacturers/suppliers are.**

Please see attachment. Please note that some earlier data is not held and this has been identified in the spreadsheet.

The Trust records its financial data in financial years; namely April 1 to 31 March and only hold annual amounts spent in the years 2013 to date.

The Trust is happy to release volume used, however when combined with amount spent it reveals our price point. It is for this reason the Trust considers the amount spent/purchased exempt from supply in accordance with section 43.-(2) Commercial Interests.

The Trust has conducted a public interest test and finds that its disclosure diminishes our position in a competitive environment by revealing market sensitive information. The aim of the Trust is to develop and give the highest quality healthcare to patients, achieving this by using advanced treatment and expertise which is both cost effective and value for money. This enables the Trust to reinvest more of its funding back into that continuing healthcare. The Trust considers that the release of any commercially sensitive information would have an adverse effect on this process, so reducing its efficacy. This in itself would reduce the effectiveness of the service to

those who come to the Trust for their healthcare provision and for this reason section 43.(2) is engaged.

Due to technical constraints, the Trust is unable to upload the attachment relating to this request. To obtain this please email [plh-tr.FOI-requests@nhs.net](mailto:plh-tr.FOI-requests@nhs.net), quoting the file reference.

**Attachments included:** No